SCHEMBL16718705

SCHEMBL16718705

CC(C)(C)c1cc(C(C)(C)C)c(NC(=O)c2ccnc3ccccc23)cc1O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 4/20 0.57
ADORA3 P0DMS8 1/20 0.57
ADRB3 P13945 1/20 0.57
TBXA2R P21731 1/20 0.57
SLC6A2 P23975 1/20 0.57
AGTR1 P30556 1/20 0.57
MC4R P32245 1/20 0.57
PTGS2 P35354 1/20 0.57
SLC6A3 Q01959 1/20 0.57
NR2E1 Q9Y466 3/20 0.45
PABPC1 P11940 3/20 0.45
EIF4H Q15056 3/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
CNR1 P21554 2/20 0.44
CNR2 P34972 2/20 0.44
RORA P35398 1/20 0.43
MAPT P10636 3/20 0.41
HSD17B10 Q99714 1/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ivacaftor SCHEMBL417309 0.85 CFTR (0.56) CFTRADORA3ADRB3TBXA2RSLC6A2
SCHEMBL18617160 0.83 CFTR (0.54) CFTRADORA3ADRB3TBXA2RSLC6A2
SCHEMBL25874770 0.78 CFTR (0.49) CFTRADORA3ADRB3TBXA2RSLC6A2
SCHEMBL15244981 0.75 CFTR (0.45) CFTRADORA3ADRB3TBXA2RSLC6A2
SCHEMBL28586487 0.75 SIRT6 (0.57) CFTRADORA3ADRB3TBXA2RSLC6A2
SCHEMBL28573860 0.74 KDM4E (0.75) MEN1KMT2AMAPTLMNAKDM4E
SCHEMBL24688078 0.73 RXFP1 (0.58) NR2E1KMT2AMAPTHSD17B10LMNA
SCHEMBL30102526 0.73 RXFP1 (0.58) NR2E1KMT2AMAPTHSD17B10LMNA
Ivacaftor SCHEMBL29379239 0.73 CFTR (1.00) CFTRADORA3ADRB3TBXA2RSLC6A2
Ivacaftor SCHEMBL29357389 0.73 CFTR (1.00) CFTRADORA3ADRB3TBXA2RSLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3068392-A1 PROCESS OF PREPARING PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES Vertex Pharmaceuticals Inc. (US) 2016-09-21 EP disclosed
WO-2015073231-A9 PROCESS OF PREPARING PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-07-16 WO disclosed
WO-2015073231-A1 PROCESS OF PREPARING PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-05-21 WO disclosed